These data are consistent with the PLK1/Fbxw7/MYC signalling axis described by Xiao and colleagues, and highlight the potential of PLK1 inhibitors as a therapeutic option for the treatment of MYC-overexpressing cancers. This evidence concerns the gene MYC and cancer.